GSK PERK inhibitor - ≥98%, high purity , CAS No.1337531-89-1, Inhibitor of eukaryotic translation initiation factor 2 alpha kinase 3;Inhibitor of myosin light chain kinase 2

Item Number
G355474
Grouped product items
SKUSizeAvailabilityPrice Qty
G355474-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
G355474-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$139.90
G355474-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$219.90
G355474-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$419.90
G355474-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$629.90
G355474-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$879.90

Basic Description

Synonyms1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2, 3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone | 1-(5-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethan-1-o
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of eukaryotic translation initiation factor 2 alpha kinase 3;Inhibitor of myosin light chain kinase 2
Product Description

PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states.

Associated Targets(Human)

EIF2AK3 Tchem Eukaryotic translation initiation factor 2-alpha kinase 3 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MYLK2 Tchem Myosin light chain kinase 2, skeletal/cardiac muscle (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NEK2 Tchem Serine/threonine-protein kinase NEK2 (3514 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK9 Tchem Serine/threonine-protein kinase NEK9 (1479 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK6 Tchem Serine/threonine-protein kinase NEK6 (1986 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK7 Tchem Serine/threonine-protein kinase NEK7 (1804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK5 Tchem Serine/threonine-protein kinase Nek5 (349 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK4 Tchem Serine/threonine-protein kinase Nek4 (980 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK1 Tchem Serine/threonine-protein kinase Nek1 (1886 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK3 Tchem Serine/threonine-protein kinase Nek3 (902 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NEK11 Tchem Serine/threonine-protein kinase Nek11 (645 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EIF2AK3 Tchem Eukaryotic translation initiation factor 2-alpha kinase 3 (635 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone
INCHI InChI=1S/C24H19F4N5O/c1-32-11-18(21-22(29)30-12-31-23(21)32)14-2-3-19-15(9-14)4-5-33(19)20(34)8-13-6-16(24(26,27)28)10-17(25)7-13/h2-3,6-7,9-12H,4-5,8H2,1H3,(H2,29,30,31)
InChi Key PXVQGBJMIQCDEX-UHFFFAOYSA-N
Canonical SMILES CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC(=C5)F)C(F)(F)F
Isomeric SMILES CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC(=C5)F)C(F)(F)F
PubChem CID 66561167
Molecular Weight 469.43

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

12 results found

Lot NumberCertificate TypeDateItem
I2413407Certificate of AnalysisJun 15, 2024 G355474
I2413408Certificate of AnalysisJun 15, 2024 G355474
I2413409Certificate of AnalysisJun 15, 2024 G355474
I2413410Certificate of AnalysisJun 15, 2024 G355474
I2413411Certificate of AnalysisJun 15, 2024 G355474
I2413412Certificate of AnalysisJun 15, 2024 G355474
I2413413Certificate of AnalysisJun 15, 2024 G355474
I2413414Certificate of AnalysisJun 15, 2024 G355474
I2413415Certificate of AnalysisJun 15, 2024 G355474
I2413416Certificate of AnalysisJun 15, 2024 G355474
I2413417Certificate of AnalysisJun 15, 2024 G355474
I2413418Certificate of AnalysisJun 15, 2024 G355474

Show more⌵

Chemical and Physical Properties

Melt Point(°C)237-240° C (dec.)

Related Documents

References

1. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T et al..  (2012)  Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)..  J Med Chem,  55  (16): (7193-207).  [PMID:22827572] [10.1021/op500134e]
2. Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, Ortori CA, Willis AE, Fischer PM, Barrett DA et al..  (2013)  Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice..  Sci Transl Med,  (206): (206ra138).  [PMID:24107777] [10.1021/op500134e]
3. Smith HL, Mallucci GR.  (2016)  The unfolded protein response: mechanisms and therapy of neurodegeneration..  Brain,  139  (Pt 8): (2113-21).  [PMID:27190028] [10.1021/op500134e]
4. Axten JM, Romeril SP, Shu A, Ralph J, Medina JR, Feng Y, Li WH, Grant SW, Heerding DA, Minthorn E et al..  (2013)  Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development..  ACS Med Chem Lett,  (10): (964-8).  [PMID:24900593] [10.1021/op500134e]

Solution Calculators